Document is current
Any future updates will be listed below
-
Authors
Watanabe, Akira https://orcid.org/0000-0003-0496-5945
Tsunashima, Ryo https://orcid.org/0000-0003-2663-0142
Kato, Chikage
Kitano, Sae https://orcid.org/0009-0008-6896-3088
Matsumoto, Saya
Sota, Yoshiaki https://orcid.org/0000-0001-5963-652X
Morita, Midori https://orcid.org/0000-0003-4083-4432
Sakaguchi, Koichi
Naoi, Yasuto https://orcid.org/0000-0002-6090-0137
- License Information
-
More Information
Article History
Received: 9 November 2023
Accepted: 22 March 2024
First Online: 8 April 2024
Declarations
:
: Yasuto Naoi has received research funding from Sysmex, ONO, Daiichi-Sankyo and AstraZeneca, and honoraria from AstraZeneca, Pfizer, Eli Lilly, ONO, Daiichi-Sankyo and Chugai outside the submitted work; he holds joint patents with Sysmex including Curebest™ 95GC Breast (JP.5725274.B2) and has received patent royalties outside the submitted work. The other authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
